FTC Says Cephalon Bought Off Would-Be Competitors

Law360, New York (February 14, 2008, 12:00 AM EST) -- The U.S. Federal Trade Commission has filed a lawsuit against Cephalon Inc. that alleges the pharmaceutical company paid off four would-be generics competitors to keep them out of the $800 million annual U.S. market for Cephalon's narcolepsy drug Provigil until 2012.

The FTC filed its complaint on Wednesday in the U.S. District Court for the District of Columbia, naming Frazer, Pa.-based Cephalon as the sole defendant.

The complaint asks the court to enjoin the defendant from maintaining or enforcing agreements with four generics makers who asked...
To view the full article, register now.